Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with a diagnosis of rheumatoid arthritis, ankylosing spondylitis or plaque psoriasis
Decision to initiate Humira® treatment in accordance with routine medical practice and in compliance with eligibility for adalimumab based on the local label
Prior to any study-specific procedures, participant has voluntarily signed the authorization (or informed consent where applicable) to disclose and use anonymized personal health information after participate in this research.
You may not be if
Inadequate response to previous standard treatment with anti-tumor necrosis factor (TNF) biological agent according to the physician's clinical judgment.
Participant has been treated with adalimumab within 70 days (five half-lives) prior to the Baseline Visit.
Participants discontinued due to adverse drug reaction of previous adalimumab treatment.
Participants who fulfill any of the contraindications as per adalimumab label in China.
Participants, who in the clinician's view, may not be able to comply with the study requirements.
